Lantheus Holdings (LNTH) In-Depth Analysis: A Company That Profits by Reliably Supplying Radiopharmaceutical “Diagnostic Agents”—Reading Growth and Cycles (Volatility) at the Same Time

* This report is prepared based on data as of 2026-02-28.

What does LNTH do? (Business explanation a middle schooler can understand)

Lantheus Holdings (LNTH) makes and delivers specialized medicines—diagnostic imaging agents—used to help doctors “find” disease. Think of them as a kind of “glowing marker” inside the body that, when paired with dedicated imaging equipment, helps physicians pinpoint abnormalities in cancer as well as cardiac and neurological conditions.

In plain English, LNTH delivers “special ink for finding disease” to clinics on schedule. If that ink doesn’t show up, the test may not happen at all—so in this business, “reliable supply” can be just as valuable as “how good the drug is.”

Main product pillars (oncology, cardiology, neurology)

• Oncology: PET diagnostic agent “PYLARIFY,” used in prostate cancer testing, is a major pillar
• Cardiology: Contrast agent “DEFINITY,” which improves the visibility of cardiac ultrasound exams, is also a major pillar
• Neurology: “Neuraceq,” used for brain diseases (often in an Alzheimer’s-related context), is also part of the portfolio

Who are the customers, and how does it make money?

Customers include the providers that run the exams (hospitals and imaging centers) and the distribution/supply networks that serve them. Patients ultimately benefit, but purchasing and adoption decisions are made by medical institutions and testing facilities.

The business model breaks into two main buckets.

• Product sales: Recurring sales of diagnostic imaging agents to hospitals and imaging facilities. As exam volumes grow, utilization rises, which can make revenue easier to compound
• Providing “the ability to make” (manufacturing infrastructure / contract manufacturing): Radiopharmaceuticals operate under tight time windows and require tightly integrated manufacturing, quality, and logistics. The company has said the 2025 acquisition of Evergreen Theragnostics added not only manufacturing infrastructure, but also a CDMO (contract development and manufacturing organization) business

Why it gets chosen: the core value proposition is “diagnostic confidence” + “on-time delivery”

LNTH tends to win business for two reasons: it offers tools that increase diagnostic confidence, and it can deliver consistently in a highly constrained radioactive supply chain. In radiodiagnostics, supply disruptions can blow up scheduling and operations and quickly raise costs for clinical sites—so dependable supply becomes a competitive advantage in its own right.

Growth drivers that tend to be tailwinds (three pillars)

• Advancement of cancer diagnostics: As the value of accurately localizing lesions—information that can directly shape treatment—continues to rise, the use cases for diagnostic imaging agents tend to expand
• Portfolio expansion (M&A and development): A path that includes strengthening R&D via the Life Molecular Imaging acquisition, and expanding manufacturing-side capabilities—not just diagnostics—through the Evergreen acquisition
• Build-out of supply network and manufacturing capability: End-to-end operations across manufacturing, quality, logistics, and facility support can create meaningful barriers to entry

Potential future pillars: themes that can reshape the profit structure even if small today

LNTH is worth tracking not just for “how big it is today,” but for whether it can meaningfully reshape future competitiveness and the profit model.

• Approval and rollout of new PET diagnostic imaging agents: Into 2026, the company has described a strategy of pursuing multiple FDA approvals and launch preparations centered on PET diagnostics. Adding more pillars reduces reliance on any single product and can make it easier to “bundle” offerings and supply the same customers reliably
• Seeding in areas that consider diagnostics and therapy as a set (though the policy is being organized): While the Evergreen acquisition referenced therapy-related candidates, the latest update clarified that the strategic center of gravity is “innovative radiodiagnostics,” and that it will consider alternative options to maximize the value of radiotherapeutic assets. In other words, it’s not currently “all-in on therapy,” but rather “diagnostics-first while exploring the best path for therapy assets”
• CDMO and leveraging manufacturing infrastructure: This can scale more efficiently as the company adds its own products, and external wins would diversify revenue. Manufacturing capability can also influence how quickly new products ramp

Long-term fundamentals: strong revenue growth, but profits tend to be “lumpy”

LNTH has posted strong historical revenue growth, but profitability (EPS and net income) has moved back and forth between losses and profits at times. That points to a profile closer to “growth with volatility” than a smooth, linear compounder.

Long-term growth pattern (5-year and 10-year “shape”)

• Revenue CAGR: 10-year average +18.0% and 5-year average +35.3%, showing meaningful scale expansion
• Free cash flow (FCF) CAGR: 10-year average +45.0% and 5-year average +146.1%. That said, very high growth rates can be inflated by low-base periods earlier in the history
• Long-term EPS CAGR: Cannot be calculated as an average growth rate (insufficient data / difficult to evaluate over this period), so the “shape” has to be inferred from the mix of profitable and loss-making periods and more recent dynamics

Long-term profitability trend (ROE and margins)

• ROE (latest FY): 21.4%. Over the past 5 years it has trended upward (correlation +0.71), but over 10 years it is not one-directional (correlation -0.36)
• Operating margin (latest FY): 20.2%. There have been negative years historically, with cycle-driven swings
• FCF margin (latest FY): 23.0%. It varies year to year

Lynch classification: LNTH is a “cyclical-leaning hybrid”

LNTH is growing revenue, but profitability (EPS and net income) has swung sharply, including shifts from loss-making to profitable periods. Under Lynch’s six categories, the closest fit is Cyclicals. That said, the past several years have also featured strong profitability and cash generation, so it’s more practical not to over-anchor on a single label and instead view it as a “cyclical hybrid with growth phases”.

• EPS includes both negative periods (e.g., 2012–2015, 2020–2021) and positive periods (e.g., 2016–2019, 2022–2025), with a dispersion metric of 1.08 indicating high volatility
• Net income was also negative in 2020–2021, followed by a rebound to profitability in 2023–2025
• Revenue is high-growth, but the latest TTM EPS growth rate is -22.0%, making the “lumpiness” more apparent than linearity

Short-term momentum (TTM / last 8 quarters): revenue holds, profits and cash decelerate

On a short-term (TTM) basis, the takeaway is Decelerating. Revenue is essentially flat, while profits and cash have clearly moved lower.

Facts over the last year (TTM)

• Revenue (TTM YoY): +0.5%
• EPS (TTM YoY): -22.0%
• FCF (TTM YoY): -29.0%

Is the “long-term shape” still present in the short term? (consistency check)

Long term, the pattern has been “revenue grows, but profits are lumpy.” In the latest TTM, that cyclical-leaning characteristic shows up again—EPS and FCF are down even though revenue hasn’t broken—which suggests profits can swing first. On that basis, the long-term classification reads as “consistent (classification maintained)”.

At the same time, the latest FY ROE is 21.4%, which on its own can make the company look like a “defensively strong top performer.” But with TTM EPS and FCF down, the key reminder is that high ROE doesn’t automatically translate into stable growth.

Direction over the last 2 years (~8 quarters): revenue tilts up, profits tilt down more strongly

• Revenue (TTM): 2-year growth rate (annualized) +6.2%, directionally tilted upward
• EPS (TTM): 2-year growth rate (annualized) -26.8%, directionally strongly downward
• Net income (TTM): 2-year growth rate (annualized) -28.8%, directionally strongly downward
• FCF (TTM): 2-year growth rate (annualized) +11.9%, roughly flat to slightly positive, but negative over the most recent year

Short-term margin check: the decline is hard to explain by revenue alone

The TTM FCF margin is 22.62%. With revenue essentially unchanged (+0.5%) while FCF is down -29.0%, it points to non-revenue drivers—potentially higher costs, heavier investment, margin compression, and working-capital dynamics—playing a role near term (no definitive conclusion is made).

Financial soundness (bankruptcy risk framing): low leverage and ample interest coverage

Based on the latest FY numbers, LNTH’s balance sheet looks defensively positioned. Even with the recent slowdown in profits and FCF, the company does not appear to be boxed in by debt.

• Debt / Equity: 0.001x (extremely low)
• Net Debt / EBITDA (latest FY): -0.57x (suggesting a near net-cash position)
• Cash ratio: 1.08
• Interest coverage: 15.7x

On that basis, bankruptcy risk does not look like a primary concern. Still, in periods when approvals/launches overlap with integration work, profit volatility can show up quickly in reported results, so it remains practical to monitor whether the company can “absorb the volatility financially.”

Cash flow tendencies: consistency between EPS and FCF, and “investment-driven vs. business deterioration”

In TTM, EPS is -22.0% and FCF is -29.0%, moving lower together—evidence that the earnings slowdown is also showing up in cash generation. With revenue nearly flat (+0.5%), the discussion likely extends beyond “a sudden demand collapse” to factors such as product mix, costs, investment, integration expenses, and working capital that can pressure cash flow.

Note that latest TTM FCF is approximately $349 million, and FCF as a share of revenue is approximately 22.6%, which still reflects meaningful cash generation even during a deceleration phase. The key question is whether this is primarily “launch-prep and investment burden” or “structural profitability deterioration”—something that needs to be clarified through subsequent quarterly trends.

Capital allocation (dividends and shareholder returns positioning)

As of the latest TTM, dividend-related metrics such as dividend yield, dividend per share, and payout ratio were not available. Based on the data in hand, it’s more appropriate to treat this as a company where dividends are unlikely to be the central investment angle (no inference or definitive statement is made about the existence or level of dividends).

That said, with cash generation (TTM FCF of approximately $349 million) alongside low leverage (extremely low Debt/Equity and negative Net Debt / EBITDA), if shareholder returns are part of the story, the structure would more naturally skew toward reinvestment and (as a general point that cannot be confirmed from the available data) share repurchases rather than dividends.

Where valuation stands (company historical only): checking “where we are” across six indicators

Next, we place LNTH’s current valuation, profitability, and leverage in context versus its own history—primarily the past 5 years, with the past 10 years as a secondary reference. We do not compare against peers or market averages.

PEG: current value cannot be calculated, and positioning cannot be determined

At a share price of $74.91, PEG is not calculable, consistent with negative recent earnings growth. As a result, PEG cannot be used to locate the “current position,” nor to assess whether it has moved up or down over the past 2 years (this is not treated as an anomaly—just the current fact pattern).

P/E (TTM): toward the “lower end” of the past 5-year range

P/E (TTM) is 21.27x, which sits toward the lower end of the past 5-year normal range (18.84x to 49.23x). It is also within the 10-year range and below the median (23.45x).

Note that P/E is based on TTM results while ROE is based on FY results; if they appear to tell different stories, that reflects the period mismatch (we do not treat it as a contradiction).

Free cash flow yield (TTM): toward the “upper end” of the historical range

TTM FCF yield is 7.02%, toward the upper end of the past 5-year range (1.95% to 7.91%). It is also near the upper end of the 10-year range (close to but not above the 8.23% upper bound).

ROE (latest FY): “around the middle” over the past 5 years

ROE is 21.43%, roughly mid-pack and in line with the past 5-year median. Over 10 years it is slightly below the median (24.53%) but still within the range; given the wide 10-year span from negative to very high levels, it lands in the mid-to-upper zone. The last 2 years indicate a downward direction.

FCF margin (TTM): typical over 5 years, higher over 10 years

FCF margin (TTM) is 22.62%, close to the past 5-year median (22.97%). Versus the past 10-year normal range (10.96% to 24.01%), it sits toward the high end and clearly above the 10-year median (15.39%). The last 2 years suggest a downward direction.

Net Debt / EBITDA (latest FY): negative, and a “break below” in the 10-year context

Net Debt / EBITDA is an inverse indicator: the smaller the value (the more negative), the more cash and the greater the financial flexibility. The latest FY figure is -0.57x, positioned on the low (negative) side within the past 5-year range, and below (a break below) the past 10-year normal range (-0.27x to 3.86x). The last 2 years suggest it has moved further into negative territory.

Success story (why it has won): the edge is not the product, but “supply and execution”

LNTH’s structural essence is best summarized as: reliably supplying radiodiagnostics that improve diagnostic accuracy, under operating conditions where timing is unforgiving. Radiopharmaceuticals require dependable manufacturing, quality, logistics, and supply systems that are tightly integrated into clinical workflows—creating real barriers to entry.

In addition, the Evergreen integration positions the company to make not only the products, but also the “ability to make and deliver”—including manufacturing infrastructure and CDMO (contract manufacturing)—a durable source of competitive advantage.

At the same time, this market is highly sensitive to external variables like reimbursement (payment systems) and supply-chain constraints. Even with strong products, if the “environment where they’re used” becomes unstable, demand and adoption can become more volatile.

Story continuity: is the recent strategy consistent with the success pattern?

The narrative drift over the past 1–2 years is a move away from “a radiopharmaceutical company that does everything” and toward “re-centering on PET radiodiagnostics and executing with discipline.”

• After expanding capabilities and pipeline through the 2025 acquisitions of Evergreen and Life Molecular Imaging, the company has clarified that into 2026 it will prioritize PET radiodiagnostics and tighten launch preparation and investment selection ahead of multiple potential approvals
• By divesting the SPECT business (sale completed in January 2026) and leaning further into PET diagnostics and microbubbles (echo segment), it has reinforced the message of concentrating on priority areas

In the numbers, revenue is roughly flat while profits and cash are declining, putting “lumpiness” front and center rather than “linear growth.” The most coherent way to read the current narrative is: the company is trying to preserve its growth engines (new products and stronger supply capability), but profits can move first due to execution costs and product-mix volatility.

Invisible Fragility: six points to watch more closely the stronger it appears

The goal here is not to argue “it’s dangerous right now,” but to map where deterioration can most easily enter the model.

• Flagship dependence amplifies revenue volatility: Even modest weakness in a flagship (e.g., PSMA PET) can ripple through company-wide growth and margins. The company has disclosed that flagship PSMA PET revenue recently declined year over year
• Physical constraints in supply chain and manufacturing translate directly into lost opportunity: Efforts to increase batch size via a new formulation highlight the risk that supply capacity can become a growth bottleneck. Supply is a strength—but if it constricts, demand can go unmet
• Reimbursement rule changes can disrupt adoption and profitability: Revisions to outpatient payment methods or thresholds underscore that the system is not static and can introduce volatility in facility adoption
• Post-acquisition integration costs can hit profits first: A pattern of profits and cash declining despite stable revenue suggests integration, investment, and mix effects may be in play
• Execution slippage during a leadership transition: A CEO retirement plan was announced in November 2025, with a transition period into 2026. In a year with overlapping approvals and launches, subtle delays in decision-making or shifting priorities can matter
• Side effects of focus strategy (fewer escape routes): The more the company concentrates on PET diagnostics after the SPECT divestiture, the greater the spillover risk if competitive, reimbursement, and supply headwinds hit at the same time

Competitive Landscape: the contest is not only “performance,” but also “supply, execution, and ecosystem”

LNTH’s competitive outcomes are less likely to hinge purely on molecule-level superiority the way traditional pharma often does. Instead, results tend to be determined across three layers: (1) clinical value (how directly it informs treatment decisions), (2) implementation (regulation, supply, facility operations), and (3) ecosystem (equipment, reading, software, etc.).

Key competitors (the lineup changes by use case)

• Echo contrast: GE HealthCare (Optison), Bracco Imaging (Lumason), etc.
• Prostate cancer PSMA PET: Bayer, etc. (competition may occur via alternative tracers)
• The broader PSMA map: Large players such as Novartis that strengthen the “diagnostics → therapy” context can change competitive dynamics
• Brain (amyloid PET): Eli Lilly / Avid Radiopharmaceuticals, etc.
• Manufacturing / CDMO: PharmaLogic, Nucleus RadioPharma, etc.—players that can compete on supply capacity itself

The key point is that in flagship categories like PSMA PET, competition and substitution can evolve in ways that make demand, supply, and adoption less stable—even for a leader. The company has disclosed a recent year-over-year decline in flagship revenue, reinforcing that “not perfectly linear” should be treated as a core premise.

Switching costs (conditions under which switching occurs)

Switching typically carries real friction because it touches facility protocols, staff training, ordering/delivery/quality processes, and billing workflows. But if supply reliability falters, exam capacity is immediately impacted, which can make substitution more likely. In PSMA, alternative tracers for similar use cases exist, so if differences emerge in supply, price, or access, switching pressure can increase.

Moat and durability: composite barriers are strong, but there is still room to “wobble” by indication-specific competition

LNTH’s moat is fundamentally a “composite of supply and execution”—capabilities built over time across regulation, quality, manufacturing, logistics, and facility support. Because entry requires time and capital, this type of moat can reasonably be viewed as medium-to-high durability.

Still, substitutes exist by indication. PSMA PET has alternative tracers, ultrasound contrast has commercial competitors, and in neurology, advances like blood biomarkers could change PET’s role. The moat is therefore not universal, and the practical imperative is to extend durability through portfolio expansion and stronger supply resilience.

Structural position in the AI era: AI is not the protagonist, but tends to be a tailwind that supports “keeping exams running”

LNTH is best framed less as “an AI winner” and more as a company positioned to benefit as AI makes clinical diagnostics more standardized and efficient—potentially increasing exam volumes and workflow throughput.

• Network effects: Limited (the product itself is not primarily driven by network effects, but economies of scale in the supply network can be meaningful)
• Data advantage: Medium (it can deploy quantitative support AI software for PSMA PET/CT images and accumulate know-how, but medical data is unlikely to become a natural monopoly)
• AI integration: Medium (the drug is central, but there is room to reduce adoption friction through quantification and standardization support)
• Mission criticality: High (supply directly ties to exam workflows)
• Barriers to entry: Medium to high (composite barriers across regulation, manufacturing, logistics, and commercial ramp)
• AI substitution risk: Low (AI may replace part of interpretation, but the core is physical supply)
• Structural layer: Application layer (clinical workflow implementation) + partially middle-leaning (manufacturing infrastructure / CDMO)

Even so, AI isn’t a trump card that eliminates competition. If the competitive battleground shifts toward “who can supply more reliably, more broadly, and at lower cost,” operational competition can intensify—an important consideration.

Management, culture, and governance: an interim CEO setup strengthens “execution focus,” while transition risk remains

LNTH’s messaging is increasingly centered on “diagnostics focus” and “winning the approval/launch window through execution.” That lines up with the company’s historical success pattern (a moat built on supply and execution) and can be viewed as improved strategic consistency.

Key points on leadership structure (based on public information)

• Mary Anne Heino: Executive Chairperson / Interim CEO. Has prior CEO experience and will lead as interim CEO starting January 01, 2026
• Brian Markison: CEO expected to step down. Will step down on December 31, 2025, and support the transition as a strategic advisor at least through March 31, 2026

Individual profile → culture → decision-making (not definitive; organized within observable bounds)

• Heino’s communications emphasize “commercial execution,” “expanding reach,” and “maximizing the near-term approval set (including a new formulation for PSMA PET),” which could pull the organization further toward execution
• Markison’s framing has emphasized “capability expansion through acquisitions and partnerships” and longer-term design; during integration phases, the lag where profits can swing in the short term often becomes a central issue

How employee reviews are handled (important caveat)

We do not have a sufficiently robust set of generalized patterns from employee reviews as reliable primary information limited to after August 2025. Accordingly, we avoid definitive cultural conclusions based on reviews and instead limit ourselves to hypotheses about patterns that can arise from the business structure and organizational changes.

• Hypothesis that tends to show up positively: clear purpose in a mission-critical domain, cross-functional collaboration tied directly to outcomes, and a culture that values process discipline and repeatability
• Hypothesis that tends to show up as stress: tight supply time windows can force reactive work, and short-term workload can spike when acquisition integration and new product launches overlap

Two-minute Drill: the “investment thesis skeleton” long-term investors should retain

The long-term question for LNTH isn’t simply “medical testing grows.” It’s whether the company can build and sustain the capability to reliably supply radiodiagnostics—and keep them embedded in clinical workflows without disruption. As a cyclical-leaning name, there can be periods where profits and cash swing more than revenue; in Lynch terms, it helps to narrow the key variables worth tracking.

• Core hypothesis: Flagship demand re-stabilizes over the medium term despite volatility from competition, supply, and policy; reliance on any one product declines as new products are added; and improved supply resilience plus integration work ultimately show up as stronger execution capability
• Current position: In TTM, revenue is +0.5% versus EPS -22.0% and FCF -29.0%, signaling a deceleration phase—consistent with a cyclical pattern where “profits fall first”
• Defense: Net Debt / EBITDA is -0.57x, Debt/Equity is 0.001x, and interest coverage is 15.7x, pointing to solid financial capacity
• Largest debate: Whether the profit and FCF slowdown reflects “investment, integration, and supply-strengthening costs,” or “structural profitability deterioration tied to competition and reimbursement”

KPI tree (what drives enterprise value: a causal map)

For LNTH, enterprise value is driven not only by product performance, but also by supply, execution, and policy fit. The causal chain investors should follow is below.

Outcomes

• Earnings and free cash flow generation capacity (depth and sustainability)
• Capital efficiency (e.g., ROE)
• Financial endurance (resilience to volatility in competition, policy, and supply)
• Portfolio stability (how much a wobble in a single flagship affects the whole company)

Value Drivers

• Revenue scale (total volume that accumulates in line with exam volumes)
• Quality of revenue growth (the “lumpiness” where growth years and plateau years appear)
• Margins (the degree to which profits rise/fall even at similar revenue levels)
• Strength of cash conversion (swinging with investment, working capital, and integration costs)
• Repeatability of supply operations (the ability to avoid stopping exams)
• Product mix (which pillars grow and which wobble)
• New product additions and launch execution (increasing the number of pillars)
• Fit with the policy and reimbursement environment (changes in adoption friction)
• Management prioritization (consistency of focus)

Operational Drivers

• PSMA PET (prostate cancer): facility adoption and exam volumes; supply resilience (capacity and access improvements); volatility driven by competition, demand, and supply factors
• Echo contrast (DEFINITY): recurring utilization from repeat use; adoption volatility driven by competing contrast agents and policy factors
• Brain (amyloid PET): establishing the use-case position; role changes driven by the adoption of alternative tests
• New product set: execution of approvals and launches; training/protocol build-out and short-term friction during ramp
• Manufacturing infrastructure / CDMO: internal supply headroom; winning external contracts; execution track record as a barrier to entry
• Portfolio reconfiguration: effects and side effects (reduced diversification) from the SPECT separation

Constraints

• Supply constraints and shipment adjustments (physical constraints)
• Complexity of reimbursement and billing rules (operational friction for facilities)
• New product ramp costs (training and protocol build-out)
• Post-acquisition integration costs (profits and cash can swing first)
• Changes in the competitive environment (indication-specific substitutes and competitors)
• Leadership transition period (priority-setting and consistency of execution)
• Reduced diversification due to focus (fewer escape routes)

Monitoring Points

• Attribution of flagship volatility (which is dominant: competition, supply, or policy)
• Whether improved supply resilience is showing up in shipment adjustment frequency and reduced missed demand
• Whether new product launches are progressing as accumulated facility adoption and exam volumes
• To what extent costs for integration, supply strengthening, and launch preparation are showing up as short-term swings in profits and cash
• Whether CDMO is becoming visible as “utilization” via external projects, utilization rates, etc.
• How reimbursement changes are reflected in facility operational burden and adoption pace
• Whether the benefits (clearer execution) and side effects (fewer escape routes) of diagnostics focus are strengthening simultaneously
• Whether priorities across approvals, launches, and supply are being executed without drift during the transition period